4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical PracticeSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorderActive, not recruitingNot stated2026-09-25NCT05049798
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingPhase 22026-09-25NCT04634552
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque PsoriasisSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorderActive, not recruitingNot stated2026-09-25NCT03218488
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerNeoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinomaActive, not recruitingPhase 1 / Phase 22026-08-28NCT03473743